Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (MIRM): 19 pipeline candidates · 9 upcoming catalysts · ~6 mo cash runway · 21 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
5.7 months
D/E 2.67 · 0% dilution
Lead: Approved
19 candidates
9 upcoming, next in ~12d
1 buy · 31 sells (180d)
A transparent, data-derived signal for Mirum Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.2B
Cash
$324.9M
Quarterly Burn
$228.8M
Runway
5.7 mo
Revenue
$159.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (19 candidates)
| Drug | Phase |
|---|---|
| brelovitug | Phase 3 |
| bulevirtide | Phase 3 |
| Chenodal | Approved |
| Cholates | Phase 2 |
| cholbam | Approved |
| Cholbam (cholic acid) | Approved |
| ctexli | Approved |
| Ctexli (chenodiol) | Approved |
| delayed treatment with brelovitug | Phase 3 |
| High dose of MRM-3379 | Phase 2 |
Showing 10 of 19 candidates. Sign up for full pipeline.
Upcoming Catalysts (9)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
312
Total value held
$6.27B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 13,735,052 | $1.27B |
| vanguard capital management llc | 4,829,552 | $446.2M |
| blackrock, inc. | 3,846,530 | $355.3M |
| fmr llc | 1,965,375 | $181.6M |
| state street corp | 1,944,281 | $179.6M |
| bvf inc/il | 1,584,727 | $146.4M |
| vanguard portfolio management llc | 1,432,083 | $132.3M |
| eventide asset management, llc | 1,408,871 | $130.1M |
| wellington management group llp | 1,334,809 | $123.3M |
| novo holdings a/s | 1,325,000 | $122.4M |
Showing top 10 of 312 institutional holders of Mirum Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Mirum Pharmaceuticals, Inc.'s pipeline?
Mirum Pharmaceuticals, Inc. (MIRM) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mirum Pharmaceuticals, Inc.'s lead drug candidate?
Mirum Pharmaceuticals, Inc.'s most advanced tracked candidate is brelovitug (Phase 3) for Chronic Hepatitis D Infection; Chronic Hepatitis D.
What is Mirum Pharmaceuticals, Inc.'s next catalyst?
Mirum Pharmaceuticals, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: volixibat" — expected June 30, 2026.
What is Mirum Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mirum Pharmaceuticals, Inc. has approximately 5.7 months of cash runway.
What is Mirum Pharmaceuticals, Inc.'s market capitalization?
Mirum Pharmaceuticals, Inc.'s market capitalization is approximately $6.2B.
Get the full picture on Mirum Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.